If stem cells could save your child’s life,
shouldn’t you know more?
Once a newborn’s umbilical cord has been cut, the remaining blood in the cord and a piece of the umbilical cord are collected.
As the process takes place after the umbilical cord has been cut, it is RISK-FREE, FAST and PAINLESS for both mom and baby.
Salveo Swiss Biotechnology offers South African parents the most affordable options to store their babies’ stem cells combined with sustainable, world-class quality standards. Storing your baby’s umbilical cord stem cells with Salveo Swiss Biotechnology will give you access to the treatments provided by currently known stem cell therapies, while storing tissue stem cells in sustainable formats for potential future use.
Salveo Biotechnology South Africa is jointly owned by JSE-listed Ecsponent Limited and international biotechnology group, Esperite. Headquartered in Geneva Switzerland and with a footprint in over 40 countries across three continents, Esperite is a Swiss private state-of-the-art laboratory, specialising in the cryopreservation of stem cells, cell culture and regenerative medicine.
Due to its association with Esperite, Salveo Biotechnology South Africa is governed by the protocols and procedures of Europe’s largest stem cell bank and the renowned Swiss quality ingrained in every aspect of the business to ensure consistent quality. All laboratory processing takes place in the Cryo-Save South Africa laboratory, which is accredited by the AABB (formerly American Associations of Blood Banks). The AABB’s testing standards and accreditation program is the gold standard for stem cell storage laboratories.
- The most affordable umbilical stem cell storage option in South Africa
- Customisable payment plans over 24, 48 and 60 months
- Discounts applicable to specific medical aid members and groups associated with our partners
- Options to store cord blood only, or a combination of cord blood and tissue.
Blood stem cells can be used in the treatment of more than 80 diseases. This doesn’t mean they will be used and using them doesn’t guarantee success. Each case is unique and only a doctor can determine eligibility.
Acute lymphoblastic leukaemia (ALL)
Acute myeloid leukaemia (AML)
Chronic myeloid leukaemia (CML)
Non-Hodgkin’s lymphoma (NHL)
Hodgkin’s lymphoma (HL)
Myelodysplastic syndrome (MDS)
Bone Marrow Failure Syndromes
Severe aplastic anaemia
Sickle-cell anaemia (hemoglobin SS)
Severe combined immunodeficiency
Germ cell tumour
Soft tissue sarcoma
Reference: A Sureda et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplantation (2015) 50, 1037–1056